Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.69 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.69 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.69 |
| ▸ | DPP4 | P27487 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.69 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.69 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.69 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.69 |
| ▸ | GAPDH | P04406 | 1/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.69 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.69 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.69 |
| ▸ | STAT6 | P42226 | 1/20 | 0.69 |
| ▸ | PI4KA | P42356 | 1/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.69 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.69 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.69 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18503540 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL27419960 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL15623876 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL3150637 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL157531 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL29435131 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL18486352 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL1996593 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL20579764 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 | |
| SCHEMBL157530 | 1.00 | ADORA2A (0.69) | ADORA2AADORA2BSLC29A1DPP4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 307 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | SHATTUCK LABS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2025109169-A1 | IMPROVED METHOD FOR IDENTIFICATION OF NUCLEOTIDE MODIFICATIONS | OXFORD UNIVERSITY INNOVATION LIMITED (GB) | 2025-05-30 | — | — | WO | claimed |
| CN-117866948-B | Negative selection method and system for purifying circular nucleic acid | 上海环码生物医药有限公司 | 2024-12-13 | — | — | CN | claimed |
| WO-2024086659-A2 | COMPOSITION AND METHODS FOR DETECTING ADENINE MODIFICATIONS | THE UNIVERSITY OF CHICAGO (US) | 2024-04-25 | — | — | WO | claimed |
| EP-4347841-A1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF | Shanghai Circode Biomed Co., Ltd. (CN) | 2024-04-10 | — | — | EP | claimed |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | UNIVERSITÄT BASEL (CH) | 2023-03-30 | — | — | US | claimed |
| WO-2023023055-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING TROPISM OF DELIVERY SYSTEMS FOR RNA | RENAGADE THERAPEUTICS MANAGEMENT INC. (US) | 2023-02-23 | — | — | WO | claimed |
| WO-2022247943-A1 | CONSTRUCTS AND METHODS FOR PREPARING CIRCULAR RNAS AND USE THEREOF | Shanghai Circode Biomed Co., Ltd. (CN) | 2022-12-01 | — | — | WO | claimed |
| EP-4090969-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | Universität Basel (CH) | 2022-11-23 | — | — | EP | claimed |
| CN-114929244-A | Mannose-based mRNA targeted delivery system and application thereof | 深圳市瑞吉生物科技有限公司 | 2022-08-19 | — | — | CN | claimed |
| CN-114076805-B | Method for enriching methylated adenosine in urine and application thereof | 浙江大学 | 2022-07-26 | — | — | CN | claimed |
| WO-2022115822-A2 | METHODS FOR FULL-LENGTH REVERSE TRANSCRIPTION PCR OF LONG RNAS CONTAINING MODIFIED RIBONUCLEOSIDES USING A THERMOSTABLE REVERSE TRANSCRIPTASE | NORTHWESTERN UNIVERSITY (US) | 2022-06-02 | — | — | WO | claimed |
| EP-4747380-A1 | MODULATING EXPRESSION OF ALAS1 (5'-AMINOLEVULINATE SYNTHASE 1) GENE | CRISPR Therapeutics AG (CH) | 2026-05-27 | — | — | EP | disclosed |
| US-12636304-B2 | — | — | 2026-05-26 | — | — | US | disclosed |
| WO-2026107055-A1 | HEPATITIS B VIRUS VACCINE AND METHODS OF USE | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-05-21 | — | — | WO | disclosed |
| WO-2026105091-A1 | COMPOSITIONS AND METHODS TO MODULATE TRANSPOSABLE ELEMENTS GOVERNING CELL-STATE TRANSITIONS | HAYA THERAPEUTICS SA (CH) | 2026-05-21 | — | — | WO | disclosed |
| US-11273209-B2 | Methods and compositions for RNA-guided treatment of HIV infection | Temple University—Of the Commonwealth System of Higher Education (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3958893-A1 | MRNA FORMULATION | eTheRNA Immunotherapies NV (BE) | 2022-03-02 | — | — | EP | disclosed |
| CN-114096272-A | mRNA formulations | 伊泽阿恩埃免疫疗法股份有限公司 | 2022-02-25 | — | — | CN | disclosed |
| EP-3942042-A1 | METHODS AND COMPOSITIONS FOR EDITING NUCLEOTIDE SEQUENCES | The Broad Institute, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636304-B2 | — | RNMT, RNGTT, NSUN2 | ADORA2A 494/4885ADORA2B 758/4885SLC29A1 390/4885 |
| US-20230099822-A1 | MR1 LIGANDS AND PHARMACEUTICAL COMPOSITIONS FOR IMMUNOMODULATION | MRGPRX1, MRGPRX2, CD47 | ADORA2A 82/4885ADORA2B 133/4885SLC29A1 650/4885 |
| US-20260139030-A1 | CHIMERIC PROTEINS FOR TREATING CUTANEOUS INFLAMMATION | TNFRSF9, CD40, TNFSF11 | ADORA2A 1523/4885ADORA2B 1846/4885SLC29A1 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.